Sideroblastic anemia secondary prevention: Difference between revisions
Nazia Fuad (talk | contribs) |
Shyam Patel (talk | contribs) No edit summary |
||
| Line 10: | Line 10: | ||
==Secondary Prevention== | ==Secondary Prevention== | ||
Effective measures for the secondary prevention of sideroblastic anemia include:<ref name=" | Effective measures for the secondary prevention of sideroblastic anemia include:<ref name="pmid22983749">{{cite journal| author=Ohba R, Furuyama K, Yoshida K, Fujiwara T, Fukuhara N, Onishi Y et al.| title=Clinical and genetic characteristics of congenital sideroblastic anemia: comparison with myelodysplastic syndrome with ring sideroblast (MDS-RS). | journal=Ann Hematol | year= 2013 | volume= 92 | issue= 1 | pages= 1-9 | pmid=22983749 | doi=10.1007/s00277-012-1564-5 | pmc=3536986 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22983749 }} </ref> | ||
* [[Iron]] chelators | * [[Iron]] chelators | ||
* [[Phlebotomy]] | * [[Phlebotomy]] | ||
| Line 18: | Line 17: | ||
* [[Cardiac monitoring]] | * [[Cardiac monitoring]] | ||
* Monitor [[iron]] studies , keep [[ferriten]] level < 500 ng/ml | * Monitor [[iron]] studies , keep [[ferriten]] level < 500 ng/ml | ||
* [[ | * [[Pyridoxine]] supplementation, 50-100mg a day | ||
==References== | ==References== | ||
Revision as of 20:07, 19 December 2018
|
Sideroblastic anemia Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Sideroblastic anemia secondary prevention On the Web |
|
American Roentgen Ray Society Images of Sideroblastic anemia secondary prevention |
|
Risk calculators and risk factors for Sideroblastic anemia secondary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Nazia Fuad M.D.
Please help WikiDoc by adding content here. It's easy! Click here to learn about editing.
Overview
Effective measures for the secondary prevention of sideroblastic anemia include iron chelators, Phlebotomy, regular liver function tests to assess for liver disease. Other measures include regular CBC in patients with MDS, cardiac monitoring, monitoring iron studies , and keeping ferriten level < 500 ng/ml.
Secondary Prevention
Effective measures for the secondary prevention of sideroblastic anemia include:[1]
- Iron chelators
- Phlebotomy
- Regular liver function tests to assess for liver disease
- Regular CBC in patients with MDS myelodysplastic syndrome
- Cardiac monitoring
- Monitor iron studies , keep ferriten level < 500 ng/ml
- Pyridoxine supplementation, 50-100mg a day
References
- ↑ Ohba R, Furuyama K, Yoshida K, Fujiwara T, Fukuhara N, Onishi Y; et al. (2013). "Clinical and genetic characteristics of congenital sideroblastic anemia: comparison with myelodysplastic syndrome with ring sideroblast (MDS-RS)". Ann Hematol. 92 (1): 1–9. doi:10.1007/s00277-012-1564-5. PMC 3536986. PMID 22983749.